Dublin, March 18, 2025 (GLOBE NEWSWIRE) — The “Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, Distribution Channel, and Region with Growth Forecasts, 2025-2030” has been added to ResearchAndMarkets.com’s offering.
The Inhalable Biologics Market was valued at USD 3.79 billion in 2024, and is projected to reach USD 10.06 billion by 2030, rising at a CAGR of 17.60%.
Growth drivers include the increasing prevalence of respiratory diseases, rising demand for non-invasive drug delivery, and advancements in formulation technologies enhancing biologic stability. The market benefits from patient preference for self-administration, faster drug onset through pulmonary delivery, and research on inhalable monoclonal antibodies, peptides, and RNAi-based therapeutics. Regulatory support and technological innovations further expand market opportunities.
The high prevalence of respiratory conditions, including asthma, COPD, and cystic fibrosis, remains a key growth driver. According to the CDC and ACAAI, asthma affected 7.7% of Americans (24.9 million) in 2023, leading to significant healthcare utilization and costs. Inhalable biologics offer targeted lung delivery with rapid onset, enhancing treatment efficacy while minimizing systemic side effects. Companies such as Ocugen, Moderna, Pfizer-BioNTech, and AstraZeneca are expanding their portfolios through inhaled vaccines and therapeutics. For instance, Ocugen received FDA clearance in January 2025 for a Phase 1 trial of OCU500, an inhaled COVID-19 vaccine, while MannKind Corporation continues to expand Afrezza’s reach, with Indian regulatory approval following positive Phase 3 trial results.
The market pipeline remains active, with inhalable biologics targeting respiratory diseases, diabetes, infectious diseases, and oncology. A notable innovation includes inhalable mRNA therapeutics using lipid nanoparticles (LNPs) functionalized with zwitterionic polymers, as published in the Journal of the American Chemical Society in November 2024, demonstrating stable nebulization and effective pulmonary delivery.
In December 2024, MannKind Corporation and Cipla Ltd. secured CDSCO approval for Afrezza (insulin human) Inhalation Powder for adults in India, following prior approvals in the U.S. and Brazil. Under this strategic initiative, MannKind will supply the product while Cipla manages marketing and distribution, with shipments expected by late 2025. The move aims to strengthen Afrezza’s global presence, particularly in India, where over 74 million adults are affected by diabetes. Afrezza offers a non-injectable, rapid-acting insulin alternative, with quick absorption and a 2-3 hour effect, addressing patient preferences for innovative and patient-centric diabetes management solutions. Cipla’s extensive distribution network is positioned to enhance access and improve patient outcomes across India. Safety measures include precautions for patients with chronic lung diseases due to the risk of bronchospasm.
As part of pipeline advancements in inhalable biologics, Ab Initio Pharma participated as a Silver Sponsor at the 35th Drug Delivery to the Lungs (DDL) Conference from December 11-13, 2024, in Edinburgh. This engagement represents a strategic initiative to highlight its drug delivery solutions, including small molecules, peptides, oligonucleotides, and RNA-based therapies. Key conference features include a presentation on intranasal mRNA delivery and a poster on inhaled oligonucleotides, emphasizing innovation in non-invasive treatment modalities.
These initiatives underscore a growing emphasis on expanding access to inhalable therapies and strengthening global market positions through strategic partnerships, regulatory approvals, and pipeline innovations focused on chronic and infectious diseases.
Inhalable Biologics Market Report Highlights
- Based on type, the peptides and proteins segment led the market with the largest revenue share of 29.85% in 2024, due to their broad therapeutic applications, stability improvements, and efficient pulmonary absorption.
- The RNAi-based therapeutics segment is projected to grow at a robust CAGR over the forecast period.
- Based on applications, the diabetes segment accounted with the largest market revenue share in 2024. However, respiratory diseases are expected to grow at a rapid CAGR over the forecast period.
- Based on dosage form, the dry powder inhalers segment accounted for the largest market revenue share in 2024, aided by approved products in the segment. However, the nebulizers segment is expected to witness at the fastest CAGR over the forecast period.
- Based on the distribution channel, the hospital pharmacies segment accounted for the largest market revenue share in 2024.
- In December 2024, Cipla received CDSCO approval on December 11, 2024, to exclusively distribute and market Afrezza (inhaled insulin) in India, developed by MannKind Corporation. Afrezza is a rapid-acting insulin for type 1 and type 2 diabetes, offering a non-injectable alternative with quick absorption and a 2-3 hour effect. Cipla aims to enhance diabetes management accessibility, leveraging its distribution network to improve patient outcomes across India.
This report addresses:
- Market intelligence to enable effective decision-making.
- Market estimates and forecasts from 2018 to 2030.
- Growth opportunities and trend analyses.
- Segment and regional revenue forecasts for market assessment.
- Competition strategy and market share analysis.
- Product innovation listings for you to stay ahead of the curve.
- COVID-19’s impact and how to sustain in this fast-evolving market.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2024-2030 |
| Estimated Market Value (USD) in 2024 | $3.79 Billion |
| Forecasted Market Value (USD) by 2030 | $10.06 Billion |
| Compound Annual Growth Rate | 17.6% |
| Regions Covered | Global |
Key Topics Covered
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Inhalable Biologics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis – Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
3.4. Pipeline Analysis
3.4.1. List of Drug Candidates (Phase 1 to Phase 3)
3.4.2. Potential Drugs to be Commercialized in the Forecast Period
3.4.3. Phase 3 Drug Forecast
3.5. Case Study Analysis
Chapter 4. Inhalable Biologics Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Peptides and Proteins
4.5. Vaccines
4.6. Monoclonal Antibodies
4.7. RNAi-based Therapeutics
4.8. Others
Chapter 5. Inhalable Biologics Market: Application Business Analysis
5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Respiratory Diseases
5.5. Diabetes
5.6. Cancer
5.7. Others
Chapter 6. Inhalable Biologics Market: Dosage Form Business Analysis
6.1. Dosage Form Market Share, 2024 & 2030
6.2. Dosage Form Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
6.4. Dry Powder Inhalers
6.5. Metered Dose Inhalers
6.6. Nebulizers
6.7. Others
Chapter 7. Inhalable Biologics Market: Dosage Form Business Analysis
7.1. Dosage Form Market Share, 2024 & 2030
7.2. Dosage Form Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
7.5. Retail Pharmacies
7.6. Online Pharmacies
Chapter 8. Inhalable Biologics Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.5. Europe
8.6. Asia-Pacific
8.7. Latin America
8.8. Middle East and Africa
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Kamada Pharmaceuticals
9.5.2. MannKind Corporation
9.5.3. Ab Initio Pharma
9.5.4. Ocugen, Inc.
9.5.5. CanSino Biologics
9.5.6. AstraZeneca
For more information about this report visit https://www.researchandmarkets.com/r/nqr0sy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Inhalable Biologics Market
